PIPA and Nalu Bio partner to bring new cannabinoids and bioactive combos to market with AI

News
Article

PIPA’s AI technology integrates biomedical databases, scientific publications, clinical trial data, and other information sources to identify the right combinations and accelerate new product development

Photo © Shutterstock.com/PabloLagarto

Photo © Shutterstock.com/PabloLagarto

The AI company, PIPA, LLC, has partnered with Nalu Bio, a biotech company specializing in cannabinoids, to bring AI-enabled combinations of cannabinoids and bioactives to consumer packaged goods (CPG) companies. Through the partnership, optimal cannabinoid and bioactive pairings will be determined through predictive AI modeling. PIPA’s AI technology integrates biomedical databases, scientific publications, clinical trial data, and other information sources to identify the right combinations and accelerate new product development.

“Combining our chemistry-derived, no-high cannabinoids with bioactives holds the key to resolving global health challenges, affecting two billion people globally,” said Caitlyn Krebs, co-founder and CEO of Nalu Bio, in a press release. “The collaboration with PIPA accelerates our ability to create new and patented formulations with enhanced efficacy for large CPG companies in food and beverage, personal care, and supplements.”

“Our expertise lies in determining the ideal bioactives to enhance the impact of Nalu Bio’s minor cannabinoids to address real needs worldwide,” stated John Melo, CEO of PIPA. “We look forward to supporting Nalu Bio’s efforts to improve lives through maximized product efficacy.”

Citing a study1 published in JAMA Network, PIPA says that consumers are well-acquainted with cannabinoids and comfortable with using them. According to that study, 72% of respondents to a cross-sectional survey reported being familiar with CBD, and 21% reported using CBD in the past year. Fewer people were familiar with other types of cannabinoids but 12%, 5%, and 4% of respondents reported having taken delta-8 THC, CBG, and CBN in the past year.

“Vitamins, caffeine, and aspirin, all originally came from the plant and now they’re chemically derived,” added Krebs. “There aren’t enough coffee beans in the world to supply the $63B energy drink industry, and Vitamin C isn’t made from oranges. We can do the same for cannabinoids, making them ubiquitous through the power of chemistry and AI.”

Reference

  1. Wilson-Poe, A.R.; Smith,T.; Elliot, M.R.; Kruger, D.J.; Boehnke, K.F. Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and Δ8-tetrahydrocannabinol among US adults. JAMA Netw Open. 2023, 6 (12), e2347373. DOI: 10.1001/jamanetworkopen.2023.47373
Related Videos
woman working on laptop computer by window
© 2024 MJH Life Sciences

All rights reserved.